Clinical Study On Shortening The Duration Of Acute Exacerbation Of Chronic Obstructive Pulmonary Disease By Qingfei Huatan Decoction

Objective:To observe the effect of Qingfei Huatan Decoction on the time of acute exacerbation of chronic obstructive pulmonary disease,and evaluate its efficacy and safety.Methods:This study is a randomized,double-blind,placebo-controlled clinical study.The source of cases is 108 patients who were diagnosed as "acute exacerbation of COPD(phlegm-heat blocking lung type)" and met the requirements of this clinical study,who were treated in the Department of Respiratory Medicine of Anhui Provincial Hospital of Traditional Chinese Medicine and Taihe County Hospital of Traditional Chinese Medicine from May 2020 to December 2022.In this study,the subjects were randomly divided into treatment group and control group with 54 cases each.Both groups were given standardized treatment according to the guidelines.On this basis,the control group was added with Qingfei Huatan Granule Simulator,and the treatment group was added with Qingfei Huatan Granule for 2 weeks.During the treatment,the TCM syndrome score,symptoms,signs score,quality of life score,lung function,six-minute walking distance,nutritional status and peripheral blood were observed and recorded according to the time node.The patients were followed up again 3 months after the treatment,and the lung function indexes were recorded.Results:1.Comparative analysis of the effective stabilization time between the two groups found that the average effective stabilization time in the treatment group was 6.35 days,and the average effective stabilization time in the control group was 7.02 days.Compared with the effective stabilization time in the two groups,the effective stabilization time in the treatment group was less than that in thecontrol group(P<0.05);The average effective and stable time in the treatment group was 11.73 days,and the average effective and stable time in the control group was 12.37 days.Compared with the two groups,the treatment group took less time to achieve significant stability than the control group(P<0.05).2.There was no significant difference in TCM syndrome score between the two groups before treatment(P>0.05);On the third day of treatment,the scores of the two groups were significantly lower than before(P<0.01),but there was no significant difference between the two groups(P>0.05);On the 6th day of treatment,the scores of the two groups continued to decrease(P<0.01).The difference between groups began to highlight and lasted until the end of treatment(P<0.05).The score of the treatment group decreased more significantly.3.The difference in the points of symptoms and signs between the two groups before treatment was not significant(P>0.05);the points of both groups decreased significantly on day 3 and 6 of treatment(P<0.01),but the difference between groups was not significant(P>0.05);the points of both groups continued to decrease on day 9 of treatment(P<0.01),and the difference between groups began to be prominent and continued until the end of treatment(P<0.05),and the points of the treatment group The reduction was more obvious in the treatment group.4.The difference in quality of life scores between the two groups before treatment was not significant(P>0.05);the scores of both groups decreased significantly on day 3 and day 6 of treatment(P<0.01),but the difference between groups was not significant(P>0.05);the scores of both groups continued to decrease on day 9 of treatment(P<0.01),and the difference between groups began to be prominent and continued until the end of treatment(P<0.05),with the treatment group decreasing The reduction was more significant in the treatment group.5.The differences in the indices of pulmonary function between the two groups before and after 14 days of treatment were not significant(P>0.05),and the differences in the indices of pulmonary function between the two groups were found to be significant in the comparison of FVC between the two groups in 3 months after the end of treatment(P<0.05),and the FVC in the treatment group was higher than that in the control group.6.The difference in six-minute walking distance between the two groups before treatment was not significant(P>0.05);after 14 days of treatment,the six-minute walking distance in both groups was significantly higher than before(P<0.01),and the difference between the groups was not statistically significant(P>0.05).7.There was no statistically significant difference between the two groups in WBC,RBC,PLT,Hb and ALB before and after treatment(P>0.05).Compared with before treatment,PLT and ALB in the treatment group increased significantly after treatment(P<0.05);Compared with before treatment,RBC and ALB in the control group increased significantly after treatment(P<0.05).8.There was no significant difference between the two groups in ECG,urine,stool routine and liver and kidney function after treatment(P>0.05).Conclusions:1.Qingfei Huatan Decoction can effectively shorten the duration of AECOPD,and has high safety in clinical application.2.Qingfei Huatan Decoction can significantly alleviate the clinical symptoms of AECOPD,improve the quality of life.